Open Access Article
Marie-Caroline A.
Cordonnier
a,
S. B. Jennifer
Kan
b,
Birgit
Gockel
a,
Shermin S.
Goh
a and
Edward A.
Anderson
*a
aChemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK. E-mail: edward.anderson@chem.ox.ac.uk; Fax: +44 (0)1865 285002; Tel: +44 (0)1865 285000
bDepartment of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
First published on 28th May 2014
The palladium-catalyzed cascade cyclization of silylated bromoenynes and alkenylstannanes provides a straightforward route to a range of bicyclic silylated cyclohexadienes. Mechanistic insights into aspects of carbopalladation and unusual palladium-mediated isomerizations have been obtained through the detection of reaction intermediates, the isolation of byproducts, and reaction monitoring by VT NMR spectroscopy. The utility of the bicyclic products is illustrated through oxidation to bicyclic enones and phenols.
Late-stage phenolation is therefore an attractive prospect that has driven the development of transition metal-catalyzed aryl halide hydroxylation and aryl C–H activation/oxidation methods.4 An alternative that avoids the prolonged heating often required by these processes is the use of a phenol surrogate, which could be revealed at a late stage of a synthetic route, but is stable to intermediate transformations. Here, arylboron derivatives have met with some success, particularly due to Molander's elegant work on the oxidation of aryl trifluoroborate salts,5 although the synthetic processability of these remains to be proven. In contrast, organosilanes – stalwarts of the protecting group field – display unrivalled tolerance towards multistep synthesis, and in recent work we have reported the use of arylsilanes as a source of phenols through Tamao-type oxidation.6,7
We have also disclosed a palladium-catalyzed cascade cyclization which prepares bi- or tricyclic products (1, Scheme 1) from the coupling of bromoenynes 2 with alkenyl- and dienylstannanes 3,8 a reaction pioneered and impressively explored by Suffert et al. for the synthesis of various polycycles.9 A feature of this work is the requirement for an internal alkyne (i.e. R1 ≠ H, Scheme 1) to avoid the formation of undesired triene isomers 4, which cannot undergo electrocyclization. One solution is to employ trimethylsilyl alkynes,10 and although this functionality indeed enables the desired cascade, it was clear that the resultant TMS-substituted cyclohexadienes would be of limited synthetic utility.
We realized that the use of a more functional silane would lead to a silicon-containing product capable of undergoing a range of further transformations, such as the aforementioned Tamao oxidation or Hiyama coupling.11 Indeed, we have illustrated this principle in approaches to the CDE rings of rubriflordilactone A, where arylsilanes formed from the cyclizations of bromoenynes could be oxidized to give specific tricyclic phenols.8b,12 In this paper we wish to report methods for the synthesis of a range of silylated bromoenynes, and their intermolecular coupling with alkenylstannanes to provide bicyclic silylcyclohexadienes 5. The oxidation of these dienes and silane substituents leads to bicyclic arylsilanes (6) and phenols (7) that would be challenging to prepare by other routes, and offers a de novo approach to ring systems of this type.13 Alongside this synthetic work, we expand on the mechanistic pathways operative in the cascade cyclization, including two unusual palladium-mediated isomerization processes. The unexpected observation of an unprecedented formal 4-endo-trig cyclization to afford fused ring cyclobutenes is also described.
The syntheses of heteroatom-tethered silylbromoenynes could be achieved uneventfully using equivalent chemistry, with sulfonamide-tethered enyne 12 and ether-linked enyne 13 being prepared in reasonable yields over two steps from known sulfonamide 14 and propargyl alcohol, respectively (Scheme 3).
In the latter two cases, the desired bicyclic products were contaminated with significant quantities of partially separable isomeric byproducts 16a, b and 17a, b (Fig. 2), which were identified by careful analysis of 1H–1H COSY, and 1H–13C HSQC and HMBC 2D NMR spectra;17 the assignment of one of these sets of byproducts (16a and 17a) is discussed here. Byproduct 16a contains an exo-methylene unit (δH 5.01 and 4.85 ppm), and two vicinal alkene protons (δH 6.00 ppm, dd, J = 15.5, 1.5 Hz; and 5.32 ppm, dq, J = 15.5 and 6.5 Hz), the latter being characteristic of the trans-alkene of the propenyl unit. These data, together with key HMBC correlations, are strongly suggestive of the formal anti-carbopalladation/cross-coupling product 16a, the formation of which is entirely consistent with our earlier results.8a The identification of the second byproduct proved less straightforward. Key signals in the 1H NMR spectrum at δH 6.36 (d, J = 10.6 Hz), 6.31 (ddd, J = 16.5, 10.6 and 9.7 Hz), 5.26 (dd, J = 16.5 and 2.0 Hz) and 5.25 ppm (dd, J = 9.8 and 2.0 Hz) revealed a connectivity between four alkene protons and thus the surprising presence of a 1,3-butadienyl unit. A further significant piece of evidence was the detection of a methyl singlet at 1.50 ppm, to which the proton at 6.33 ppm showed an nOe enhancement. These combined observations, and 1H–13C correlations, led us to propose structure 17a, which features an (E)-alkenylsilane as part of a conjugated triene.
![]() | ||
| Fig. 2 Cyclization byproducts 16a/b and 17a/b. Selected key 1H NMR chemical shifts/multiplicities (in CDCl3) for 16a and 17a are shown. | ||
A mechanistic hypothesis for the formation of these byproducts is depicted in Scheme 4. The formation of byproduct 16 is consistent with our earlier observation8a that such undesired anti-trienes form in the course of the cyclization reaction, potentially via isomerization of the intermediate dienylpalladium complex 18 to its isomer 19.18 The rate of transmetallation of complex 19 is likely to exceed that of 18, so even small amounts of 19 may lead to significant quantities of anti-triene 16 (i.e., a Curtin–Hammett situation). The formation of increased quantities of this triene for substrates 11b and 11c may reflect the increased flexibility of the larger tethering ring, which can distort to alleviate 1,3-allylic strain between the silyl substituent and exo-methylene in 19 – and therefore reduce the steric cost of placing a silane in this more hindered position. The formation of 17 may be explained by our second previous observation8a that anti-trienes can isomerize to bicyclic products on prolonged exposure to the reaction conditions. We suggest that this process may proceed via oxidative addition of Pd(0) with diene 16 to give a palladacyclopentene 20.19 This could undergo a 1,3-allylic migration of the palladium atom to the 7-membered palladacycle 21, reductive elimination from which would afford the cyclohexadiene product 15.20 The formation of byproduct 17 could be rationalised by β-hydride elimination from this common palladacycle intermediate 21, followed by reductive elimination of the resultant palladium(II) hydride species. We presume that the steric hindrance imposed by the methyl group in 17 prevents a 6π-electrocyclization of this compound.
As [4 + 1] oxidative additions of Pd(0) to dienes are rare,19 more concrete evidence to support these pathways was sought. Firstly, the formation of 16via the intermediacy of dienylpalladium complex 19 was probed through the exposure of alkynylsilane 22 to one equivalent of Pd(PPh3)4 in d8-toluene at 110 °C (Fig. 3). The characteristic methylene signals of 22 at δH 5.41 and 5.71 ppm were rapidly converted (10 min) to two new sets of peaks: a prominent (apparent) singlet at 4.60 ppm, and two smaller singlets at 4.58 and 4.78 ppm. These were tentatively assigned as the exo-methylene peaks of the syn- and anti-dienylpalladium complexes 23 and 24 respectively, based on analysis by COSY and HSQC experiments. Support for this assignment was gained through the addition of 1.5 equivalents of tributylvinyltin to the NMR tube; further heating for 10 minutes led to exclusive formation of cyclohexadiene 25 and triene 26 in a ratio mirroring that of these intermediate species (84
:
16).
![]() | ||
| Fig. 3 Use of stoichiometric Pd(PPh3)4/VT 1H NMR spectroscopy to probe the putative dienylpalladium(II) intermediates. | ||
To explore the isomerization of 26 to 25, a 1
:
0.32 mixture of these compounds, formed from reaction of silane 22 with vinyltributyltin for two hours, was purified by silica gel chromatography (Scheme 5); the triene 26 in this mixture would be expected to isomerize to give the 25 upon resubmission to the reaction conditions. Heating the mixture in toluene overnight at 110 °C in the absence of catalyst led to no conversion of 26 to the bicyclic product 25, with both compounds recovered unchanged after this period (thus ruling out a purely thermal process). Palladium(II) salts have previously been shown to promote alkene isomerisation,21 but subjection of the anti-triene to PdCl2(PPh3)2 at 110 °C also led to no reaction. However, heating the mixture in the presence of Pd(PPh3)4 for 20 h led to complete consumption of anti-triene, and by performing this isomerization in d8-toluene with monitoring by 1H NMR spectroscopy in the presence of an internal standard (1,4-dimethoxybenzene), a smooth conversion of 26 to 25 was observed (Fig. 4). This clearly demonstrates that the isomerization of anti-triene to product is not a thermal process, and in fact requires a Pd(0) catalyst, thus offering some support to our proposed mechanism. At no point do we detect the formation of syn-triene, which lends some weight to our mechanistic hypothesis for the direct conversion of anti-trienes to bicyclic products (Scheme 4, although we recognise that any syn-triene formed could electrocyclize rapidly).
![]() | ||
| Fig. 4 1H NMR spectroscopic monitoring of the conversion of 26 to 25 catalyzed by Pd(PPh3)4. 1,4-Dimethoxybenzene was used as internal standard. | ||
![]() | ||
| Fig. 5 Initial synthesis of 7,4-fused cyclobutene 30, and key HMBC spectra correlations. E = CO2Me. ● = strong correlation; • = weak correlation. | ||
The formation of this product is not unreasonable if potential mechanisms for its formation are considered (Scheme 6). Following carbopalladation (31), one possibility would involve a 4-endo-trig carbopalladation (Path A), leading to cyclobutene 32 – a pathway that might be favoured, in spite of ring strain, due to the formation of an allylpalladium intermediate. β-Hydride elimination would afford the observed product 30, and liberate a palladium(II) hydride species that could be reduced to palladium(0) by transmetallation with 28, thus leading to the ‘protodestannylated’ product 29. However, due to a lack of precedent for this mode of carbopalladation, we also consider an electrophilic palladation route feasible (Path B), in which attack by the exo-methylene on the proximal palladium(II) atom leads to palladacycle 33 – which may again be rendered possible by the formation of an allyl cation in this process. Now, loss of a proton generates palladacyclopentene 35, reductive elimination from which leads to 30.23 The resemblance of intermediate 35 to those proposed in enyne cycloisomerization processes is clear;24 the proton lost from this pathway could then effect protodestannylation of the coupling partner 28 to afford 29.
Whatever mechanism is operational, it was clear to us that this process overall corresponds to a Heck reaction in which regeneration of the palladium(0) catalyst is mediated by the stannane reagent. This suggested that an amine base might perform a similar role, and to our delight, the use of common Heck conditions (toluene, triethylamine) at just 5 mol% catalyst loading indeed led to a high-yielding cyclization of 27 to 30 (90%, Scheme 7). The more functional bromoenyne 11c was also tested in this chemistry, which gave the corresponding 7,4-fused silylcyclobutene 36 in excellent yield (86%). This efficient process offers an alternative entry to this type of fused cyclobutene ring system.25
The silylcyclohexadiene frameworks could also be readily oxidized to the corresponding arylsilanes using manganese dioxide, conditions that we had successfully employed in other work27 and which proved superior to the use of other oxidants such as DDQ. The resultant arylsilanes could generally be isolated in excellent yield; two examples are shown in Scheme 9 (38: 88%; 39: 93%). These arylsilanes show potential for a range of transformations – but here, in keeping with our interests in the synthesis of phenols from arylsilanes,6 we chose to investigate Tamao oxidation. Under Tamao conditions (TBAF, KHCO3, H2O2, 60 °C),28 good yields of the corresponding phenols 40 and 41 were obtained, thus validating this approach to the synthesis of bi/polycyclic phenols.
:
1 pet. ether–ether); 1H NMR (500 MHz, CDCl3) δH 5.69 (1H, dt, J = 2.0, 1.0 Hz), 5.48 (1H, d, J = 2.0 Hz), 3.89 (1H, t, J = 7.5 Hz), 3.76 (6H, s), 3.03 (2H, dd, J = 7.5, 1.0 Hz); 13C NMR (125 MHz, CDCl3) δC 168.7, 129.2, 119.9, 52.7, 50.4, 40.5. Data in accordance with the literature.29
:
1 pet. ether–ether) to afford 9a as a colourless oil (2.91 g, 10.1 mmol, 86%). Rf 0.31 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 3289, 2954, 1737; 1H NMR (500 MHz, CDCl3) δH 5.83 (1H, t, J = 0.6 Hz), 5.63 (1H, d, J = 1.6 Hz), 3.77 (6H, s), 3.31 (2H, br s), 2.93 (2H, d, J = 2.7 Hz), 2.05 (1H, t, J = 2.7 Hz); 13C NMR (125 MHz, CDCl3) δC 169.5, 126.1, 122.9, 78.6, 72.1, 56.0, 53.0, 42.9, 22.2; HRMS (ES+) calcd for C11H13BrO4 [M + H]+ 289.0074, found 289.0070. Data in accordance with the literature.8a
:
1 pet. ether–ether) to afford 9b as a colourless oil (730 mg, 2.41 mmol, 69%). Rf 0.26 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 3285, 2954, 1730, 1624, 1433, 1201, 1150, 959, 649; 1H NMR (500 MHz, CDCl3) δH 5.70–5.68 (1H, m), 5.61 (1H, d, J = 1.8 Hz), 3.75 (6H, s), 3.19 (2H, d, J = 0.5 Hz), 2.30–2.28 (2H, m), 2.21–2.19 (2H, m), 1.97 (1H, t, J = 2.8 Hz); 13C NMR (125 MHz, CDCl3) δC 170.4, 126.7, 122.2, 82.8, 68.9, 56.4, 52.8, 43.3, 30.7, 14.0; HRMS (ES+) calcd for C12H15BrNaO4 [M + Na]+ 325.0070, found 325.0062.
:
1 pet. ether–ether) to afford 9c as a colourless oil (227 mg, 0.716 mmol, 90%). Rf 0.26 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 3291, 2952, 1731, 1625, 1434, 1278, 1150, 901, 640; 1H NMR (500 MHz, CDCl3) δH 5.69–5.67 (1H, m), 5.59 (1H, d, J = 1.7 Hz), 3.75 (6H, s), 3.17 (2H, s), 2.21 (2H, dt, J = 7.0, 2.6 Hz), 2.12–2.10 (2H, m), 1.96 (1H, t, J = 2.6 Hz), 1.44–1.42 (2H, m); 13C NMR (125 MHz, CDCl3) δC 170.8, 126.9, 121.9, 83.5, 68.8, 56.8, 52.7, 43.1, 30.8, 23.4, 18.5; HRMS (ES+) calcd for C13H17BrNaO4 [M + Na]+ 339.0202, found 339.0200.
:
1 pet. ether–ether with 1% Et3N) to afford the 10a as a colourless oil (158 mg, 0.39 mmol, 75%). Rf 0.38 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2360, 1658, 1568, 1382, 1369, 1290, 1030; 1H NMR (400 MHz, CDCl3) δH 5.83–5.81 (1H, m), 5.63 (1H, d, J = 1.5 Hz), 4.09 (1H, septet, J = 6.1 Hz), 3.76 (6H, s), 3.30 (2H, s), 2.97 (2H, s), 1.18 (6H, d, J = 6.1 Hz), 0.22 (6H, s); 13C NMR (125 MHz, CDCl3) δC 169.4, 126.2, 122.7, 100.8, 87.4, 65.9, 56.0, 53.0, 43.0, 25.4, 23.4, 0.6; HRMS (ES+) calcd for C16H25BrNaO5Si [M + Na]+ 427.0533, found 427.0547.
:
1 pet. ether–ether), to afford the intermediate alkynyl hydrosilane as a colourless oil (224 mg, 0.645 mmol, 93%). 1H NMR (400 MHz, CDCl3) δH 5.65–5.58 (1H, m), 5.43 (1H, d, J = 1.5 Hz), 3.87 (1H, septet, J = 3.7 Hz), 3.56 (6H, s), 3.10 (2H, s), 2.76 (2H, s), 0.01 (6H, d, J = 3.7 Hz); 13C NMR (100 MHz, CDCl3) δC 169.4, 126.1, 122.8, 102.5, 86.0, 56.0, 53.0, 42.9, 23.6, −3.0; HRMS (ES+) calcd for C13H19BrNaO4Si [M + Na]+ 369.0128, found 369.0128. To a solution of this hydrosilane (30 mg, 0.086 mmol) in i-PrOH (100 μL) was added [RuCl2(p-cymene)]2 (0.3 mg, 0.0004 mmol). The reaction was stirred at rt for 10 min, then concentrated. Pentane (1 mL) was added, and the crude product was filtered through Celite (ether eluent). Concentration of the filtrate gave 10a as a pale pink oil (35 mg, 0.086 mmol, 99%).
:
1 pet. ether–ether) to afford 11a as a colourless oil (701 mg, 1.62 mmol, 94%). Rf 0.26 (5
:
1 pet. ether–ether); Anal. calcd for C18H29BrO5Si: C, 49.88; H, 6.74, found: C, 49.96; H, 6.72; IR (thin film) νmax/cm−1 2956, 2178, 1742, 1626, 1025, 733; 1H NMR (500 MHz, CDCl3) δH 5.84–5.82 (1H, m), 5.63 (1H, d, J = 1.7 Hz), 4.10 (1H, septet, J = 6.1 Hz), 3.76 (6H, s), 3.32 (2H, s), 3.00 (2H, s), 1.18 (6H, d, J = 6.1 Hz), 0.98 (6H, t, J = 7.9 Hz), 0.62 (4H, app. qd, J = 7.9 Hz, 2.2 Hz); 13C NMR (125 MHz, CDCl3) δC 169.3, 126.2, 122.7, 101.6, 85.5, 66.0, 56.1, 53.0, 42.9, 25.4, 23.5, 6.8, 6.6; HRMS (ES+) calcd for C18H29NaBrO5Si [M + Na]+ 455.0860, found 455.0862.
:
1 pet. ether–ether) to afford 11b as a colourless oil (723 mg, 1.62 mmol, 90%); Rf 0.26 (5
:
1 Pet. ether–ether); Anal. calcd for C19H31BrO5Si: C, 51.00; H, 6.98, found: C, 50.92, H; 7.02; IR (thin film) νmax/cm−1 2956, 2173, 1735, 1625, 1435, 1088, 1027, 732; 1H NMR (500 MHz, CDCl3) δH 5.84–5.82 (1H, m), 5.63 (1H, d, J = 1.7 Hz), 4.10 (1H, septet, J = 6.1 Hz), 3.76 (6H, s), 3.18 (2H, s), 2.31–2.29 (2H, m), 2.23–2.24 (2H, m), 1.18 (6H, d, J = 6.1 Hz), 0.98 (6H, t, J = 7.9 Hz), 0.62 (4H, app. qd, J = 7.9 Hz, 2.2 Hz); 13C NMR (125 MHz, CDCl3) δC 170.4, 126.6, 122.2, 106.0, 81.9, 65.9, 56.5, 52.8, 43.4, 30.9, 25.5, 15.3, 6.8, 6.5; HRMS (ES+) calcd for C19H31BrNaO5Si [M + Na]+ 469.1016, found 469.1015.
:
1 pet. ether–ether) to afford 11c as a colourless oil (337 mg, 0.730 mmol, 72%); Rf 0.26 (5
:
1 pet. ether–ether); Anal. calcd for C20H33BrO5Si: C, 52.05; H, 7.21, found: C, 51.94; H, 7.30; IR (thin film) νmax/cm−1 2955, 2172, 1735, 1625, 1434, 1278, 1026, 732; 1H NMR (500 MHz, CDCl3) δH 5.68–5.66 (1H, m), 5.59 (1H, d, J = 1.5 Hz), 4.14 (1H, septet, J = 6.4 Hz), 3.75 (6H, s), 3.18 (2H, s), 2.29 (2H, t, J = 7.3 Hz), 2.14–2.12 (2H, m), 1.49–1.47 (2H, m), 1.20 (6H, d, J = 3.4 Hz), 1.00 (6H, t, J = 6.4 Hz), 0.65–0.62 (4H, m); 13C NMR (125 MHz, CDCl3) δC 170.8, 127.0, 121.9, 106.8, 81.8, 65.9, 56.9, 52.9, 43.2, 30.9, 25.5, 23.4, 19.9, 6.9, 6.6; HRMS (ES+) calcd for C20H33BrNaO5Si [M + Na]+ 483.1173, found 483.1179.
:
1 pet. ether–ether) to afford the title compound as a colourless oil (903 mg, 2.75 mmol, 80%); Rf 0.35 (2
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 3280, 1629, 1344, 1181, 1150, 892, 679; 1H NMR (500 MHz, CDCl3) δH 7.75 (2H, d, J = 8.1 Hz), 7.31 (2H, d, J = 8.1 Hz), 5.97–5.95 (1H, m), 5.69–5.67 (1H, m), 4.13 (2H, d, J = 2.3 Hz), 4.08 (2H, s), 2.44 (3H, s), 2.05 (1H, t, J = 2.3 Hz); 13C NMR (125 MHz, CDCl3) δC 143.9, 135.8, 129.6, 127.7, 126.9, 120.5, 76.0, 74.2, 53.8, 36.1, 21.6; HRMS (ES+) calcd for C14H18BrNNaO3S [M + MeOH + Na]+ 382.0083, found 382.0077.
:
1 pet. ether–ether) to afford 12 as a colourless oil (107 mg, 0.226 mmol, 50%); Rf 0.26 (5
:
1 pet. ether–ether); Anal. calcd for C20H30BrNO3SSi: C, 50.84; H, 6.40; N, 2.96, found: C, 50.90; H, 6.32; N, 2.95. IR (thin film) νmax/cm−1 2960, 1353, 1163, 1119, 1092, 1002, 899, 734, 661; 1H NMR (400 MHz, CDCl3) δH 7.77 (2H, d, J = 8.1 Hz), 7.33 (2H, d, J = 8.1 Hz), 5.98 (1H, d, J = 1.8 Hz), 5.72 (1H, d, J = 1.8 Hz), 4.23 (2H, s), 4.11 (2H, s), 3.95 (1H, sept, J = 6.0 Hz), 2.45 (3H, s), 1.14 (6H, d, J = 6.0 Hz), 0.89 (6H, t, J = 7.8 Hz), 0.51 (4H, q, J = 7.8 Hz); 13C NMR (125 MHz, CDCl3) δC 144.0, 136.3, 130.4, 130.1, 128.1, 119.7, 98.9, 66.5, 45.4, 41.0, 38.6, 26.2, 25.8, 7.8, 7.0; HRMS (ES+) calcd for C20H30BrNNaO3SSi [M + Na]+ 494.0791, found 494.0789.
:
1 pet. ether–ether) to afford the 2-bromo-3-(prop-2-ynyloxy)prop-1-ene as a colourless oil (2.15 g, 12.3 mmol, 86%); Rf 0.26 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 3300, 2923, 2130, 1639, 1443, 1l62, 1086, 899, 668; 1H NMR (400 MHz, CDCl3) δH 5.97–5.95 (1H, m), 5.67–5.65 (1H, m), 4.23–4.19 (4H, m), 2.47 (1H, t, J = 2.4 Hz); 13C NMR (125 MHz, CDCl3) δC 128.4, 118.7, 78.8, 75.1, 73.3, 57.0; HRMS (ES+) calcd for C6H7BrO [M + H]+ 173.9681, found 173.9679. Data in accordance with the literature.31
:
1 pet. ether–ether) to afford 13 as a colourless oil (537 mg, 1.68 mmol, 59%); Rf 0.26 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2969, 1461, 1380, 1240, 1122, 1088, 878, 734; 1H NMR (400 MHz, CDCl3) δH 5.93 (1H, d, J = 1.7 Hz), 5.64–5.62 (1H, m), 4.23 (2H, s), 4.21 (2H, s), 4.12 (1H, septet, J = 6.1 Hz), 1.17 (6H, d, J = 6.1 Hz), 0.96 (6H, t, J = 7.8 Hz), 0.58 (4H, q, J = 7.9 Hz); 13C NMR (125 MHz, CDCl3) δC 128.7, 118.8, 101.3, 89.1, 73.3, 66.3, 57.9, 25.7, 6.8, 6.7; HRMS (ES+) calcd for C13H23BrNaO2Si [M + Na]+ 341.0543, found 341.0531.
:
1 pet. ether–ether) to afford 15a as a colourless oil (20 mg, 0.0546 mmol, 92%); Rf 0.33 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2358, 1737, 1252, 1024, 890, 822, 781; 1H NMR (500 MHz, CDCl3) δH 5.95 (1H, d, J = 3.3 Hz, H6), 3.95 (1H, septet, J = 6.3 Hz, CHMe2), 3.74 (3H, s, CO2Me), 3.74 (3H, s, CO2Me), 3.67–3.65 (1H, m, H5), 3.20 (2H, br s, H3), 3.03–3.01 (1H, m, H4), 2.96–2.94 (1H, m, H′4), 2.46–2.44 (1H, m, H3), 2.20–2.18 (1H, m, H′3), 1.13 (3H, d, J = 6.3 Hz, CHMe2), 1.12 (3H, d, J = 6.3 Hz, CHMe2), 1.04 (3H, d, J = 7.1 Hz, Me), 0.23 (6H, s, SiMe2); 13C NMR (125 MHz, CDCl3) δC 172.8, 172.8, 143.9, 132.1, 131.3, 131.1, 65.1, 58.5, 52.7, 52.7, 43.0, 41.7, 31.1, 30.0, 25.6, 20.1, −0.90; HRMS (ES+) calcd for C19H30NaO5Si [M + Na]+ 389.1743, found 389.1755.
:
1 pet. ether–ether) to afford 15b as a colourless oil (27.4 mg, 0.0639 mmol, 97%); Rf 0.30 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2391, 1737, 1434, 1367, 1252, 1023, 782; 1H NMR (500 MHz, CDCl3) δH 7.30 (2H, m, ArH), 7.24 (3H, m, ArH), 6.10 (1H, d, J = 3.1 Hz, H6), 3.99 (1H, septet, J = 6.2 Hz, CHMe2), 3.76 (3H, s, CO2Me), 3.74 (3H, s, CO2Me), 3.65–3.63 (1H, m, H5), 3.28–3.26 (2H, m, H1), 3.10 (1H, d, J = 17.4 Hz, H4), 2.94 (1H, d, J = 17.4 Hz, H′4), 2.45–2.43 (1H, m, H3), 2.29–2.27 (1H, m, H′3), 1.16 (3H, d, J = 6.2 Hz, CHMe2), 1.14 (3H, d, J = 6.2 Hz, CHMe2), 0.25 (6H, s, SiMe2); 13C NMR (125 MHz, CDCl3) δC 172.7, 145.4, 140.7, 133.4, 131.7, 131.1, 128.5, 127.6, 126.3, 65.2, 58.5, 52.7, 42.9, 41.2, 41.7, 32.0, 25.6, −0.9; HRMS (ES+) calcd for C24H32NaO5Si [M + Na]+ 451.1892, found 451.1911.
:
1 pet. ether–ether) to afford 15c as a colourless oil (237 mg, 0.519 mmol, 77%); Rf 0.42 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2955, 1736, 1434, 1381, 1243, 1005, 874, 730, 699; 1H NMR (400 MHz, CDCl3) δH 7.32–7.30 (2H, m, ArH), 7.27–7.23 (3H, m, ArH), 6.12–6.10 (1H, m, H6), 4.01 (1H, septet, J = 6.2 Hz, CHMe2), 3.76 (3H, s, CO2Me), 3.73 (3H, s, CO2Me), 3.64–3.62 (1H, m, H5), 3.25 (2H, br s, H3), 3.10 (1H, d, J = 17.5 Hz, H1), 2.94 (1H, d, J = 17.5 Hz, H′1), 2.45–2.43 (1H, m, H4), 2.27–2.25 (1H, m, H′4), 1.16 (3H, d, J = 6.2 Hz, CHMe2), 1.15 (3H, d, J = 6.2 Hz, CHMe2), 1.00–0.95 (6H, m, SiCH2Me), 0.77–0.74 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 172.8, 172.7, 145.5, 141.3, 131.8, 131.5, 130.9, 128.5, 127.6, 126.3, 65.2, 58.5, 52.7, 52.7, 42.9, 42.2, 41.8, 32.1, 25.7, 25.6, 6.8, 5.0, 4.9; HRMS (ES+) calcd for C27H40NaO6Si [M + MeOH + Na]+ 511.2486, found 511.2432.
:
1 pet. ether–ether) to afford 15d as a colourless oil (29.0 mg, 0.0670 mmol, 63%); Rf 0.29 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2958, 1436, 1378, 1230, 1015, 874, 730, 699; 1H NMR (500 MHz, CDCl3) δH 7.72 (2H, d, J = 8.0 Hz, ArH), 7.31 (2H, d, J = 8.0 Hz, ArH), 5.93 (1H, d, J = 3.5 Hz, H6), 4.22–4.20 (2H, m, H1), 4.11–4.00 (2H, m, H3), 3.95 (1H, septet, J = 5.9 Hz, CHMe2), 2.42 (4H, s, H5, ArMe), 2.15 (1H, dd, J = 17.0, 8.5 Hz, H5), 1.81–1.73 (1H, m, H′5), 1.13 (3H, d, J = 6.0 Hz, CHMe2), 1.11 (3H, d, J = 6.0 Hz, CHMe2), 1.02 (3H, d, J = 7.1 Hz, CHMe), 0.89 (6H, app. td, J = 8.0, 1.7 Hz, SiCH2Me), 0.68–0.65 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 145.1, 143.2, 134.4, 129.9, 129.6, 128.1, 127.8, 127.5, 65.3, 56.3, 55.4, 29.8, 28.7, 25.7, 25.7, 21.5, 19.9, 6.8, 5.0, 5.0; HRMS (ES+) calcd for C23H35NNaO3SSi [M + Na]+ 456.1999, found 456.2000.
:
1 pet. ether–ether) to afford 15e as a colourless oil (10.0 mg, 0.0356 mmol, 23%); Rf 0.29 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2955, 1732, 1463, 1210, 866; 1H NMR (500 MHz, CDCl3) δH 5.99 (1H, d, J = 3.3 Hz, H5), 4.75–4.73 (2H, m, H1), 4.60–4.58 (2H, m, H3), 3.99 (1H, septet, J = 6.0 Hz, CHMe2), 2.59–2.48 (1H, m, H8), 2.26 (1H, dd, J = 17.0, 9.0 Hz, H7), 1.92–1.84 (1H, m, H7), 1.16 (3H, d, J = 6.0 Hz, CHMe2), 1.15 (3H, d, J = 6.0 Hz, CHMe2), 1.09 (3H, d, J = 7.0 Hz, CHMe), 0.94 (6H, t, J = 7.9 Hz, SiCH2Me), 0.75–0.65 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 144.6, 131.3, 129.7, 127.4, 76.3, 75.7, 65.2, 29.9, 27.7, 25.7, 20.1, 6.7, 4.9; HRMS (ES+) calcd for C16H28NaO2Si [M + Na]+ 303.1751, found 303.1749.
:
1 pet. ether–ether) to afford 15f as a colourless oil (68.0 mg, 0.166 mmol, 75%); Rf 0.52 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2956, 1735, 1435, 1250, 1170, 1121, 1083, 1018, 872, 731; 1H NMR (500 MHz, CDCl3) δH 5.99 (1H, d, J = 3.4 Hz, H6), 3.94 (1H, sept, J = 6.1 Hz, OCHMe2), 3.72 (3H, s, CO2Me), 3.71 (3H, s, CO2Me), 2.60 (2H, m, H1), 2.31–2.29 (3H, m, H4 and H7), 2.24–2.20 (1H, m, H3), 2.12 (1H, dt, J = 13.4, 6.3 Hz, H3), 1.98 (1H, dd, J = 16.0, 7.5 Hz, H8), 1.80–1.69 (1H, m, H8), 1.12 (6H, t, J = 6.1 Hz, OCHMe2), 1.01 (3H, d, J = 6.8 Hz, C11), 0.95–0.90 (6H, m, SiCH2Me), 0.75–0.72 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 172.4, 172.0, 144.9, 134.1, 127.8, 125.7, 65.2, 53.5, 52.7, 52.7, 36.4, 36.1, 29.5, 28.5, 25.8, 25.8, 25.2, 19.6, 7.0, 7.0, 5.7, 5.6; HRMS (ES+) calcd for C22H36NaO5Si [M + Na]+ 431.2224, found 431.2236. NMR data for 16a and 17a was obtained from a purified mixture of 16a and 17a (2.8
:
1 ratio).
:
1 pet. ether–ether) to afford 15g as a colourless oil (27.5 mg, 0.0651 mmol, 58%, mixture with 16b and 17b); Rf 0.52 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2954, 1736, 1455, 1228, 1172, 1007, 873, 729; 1H NMR (500 MHz, CDCl3) δH 5.98 (1H, d, J = 3.2 Hz, H3), 3.95 (1H, septet, J = 5.9 Hz, CHMe2), 3.71 (3H, s, CO2Me), 3.70 (3H, s, CO2Me), 2.49–2.44 (2H, m, H9), 2.29–2.20 (2H, m, H5), 2.17–2.04 (3H, m, H5, H2, H1), 1.78–1.72 (1H, m, H1), 1.68–1.60 (2H, m, H7), 1.38–1.33 (2H, m, H6), 1.13 (3H, d, J = 6.0, CHMe2), 1.13 (3H, d, J = 6.0, CHMe2), 0.99 (3H, d, J = 7.0 Hz, CHMe), 0.96–0.87 (6H, m, SiCH2Me), 0.76–0.60 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 172.3, 172.0, 145.3, 137.8, 135.6, 129.2, 65.1, 55.0, 52.3, 52.1, 39.7, 39.1, 37.2, 31.4, 29.8, 28.6, 26.7, 25.6, 25.4, 22.7, 19.4, 17.3, 13.6, 6.9, 6.8, 5.2, 5.1; HRMS (ES+) calcd for C23H38NaO5Si [M + Na]+ 445.2381, found 445.2386.
:
1 pet. ether–Et2O) to obtain 30 as a colourless oil (25.0 mg, 0.0811 mmol, 90%); Rf 0.46 (2
:
1 pet. ether–Et2O); IR (thin film) νmax/cm−1 2954, 1736, 1248, 840; 1H NMR (500 MHz, MeOD) δH 4.99 (1H, s, H2), 3.71 (6H, s, CO2Me), 2.73 (2H, t, J = 2.9 Hz, H9), 2.38–2.32 (2H, m, H6), 2.29–2.25 (2H, m, H4), 1.67 (2H, app. qd, J = 6.0, 4.5 Hz, H5), 0.12 (9H, s, SiMe); 13C NMR (126 MHz, MeOD) δC 173.1, 159.9, 150.9, 145.3, 110.9, 63.2, 53.3, 36.4, 35.7, 31.9, 23.6, −1.7; HRMS (ES+) calcd for C16H24NaO4Si [M + Na]+ 331.1336, found 331.1340.
:
1 pet. ether–Et2O) to obtain 36 as a colourless oil (23.0 mg, 0.0604 mmol, 87%); Rf 0.24 (9
:
1 pet. ether–Et2O); IR (thin film) νmax/cm−1 2955, 1736, 1565, 1243, 1031; 1H NMR (500 MHz, CDCl3) δH 5.09 (1H, s, H2), 3.99 (1H, sept, J = 6.0 Hz, SiOCHMe), 3.74 (6H, s, CO2Me), 2.84 (2H, t, J = 2.9 Hz, H9), 2.39–2.35 (2H, m, H6), 2.33–2.30 (2H, m, H4), 1.71 (2H, dt, J = 10.8, 5.6 Hz, H5), 1.15 (6H, d, J = 6.0 Hz, SiOCHMe), 0.96 (6H, t, J = 7.9 Hz, SiCH2Me), 0.68 (4H, q, J = 7.9 Hz, SiCH2Me); 13C NMR (101 MHz, CDCl3) δC 171.8, 160.6, 146.9, 144.5, 110.5, 65.6, 62.0, 52.9, 36.9, 34.7, 31.5, 26.0, 22.6, 6.8, 5.7; HRMS (ESI+) calcd for C20H32NaO5Si [M + Na]+ 403.1911, found 403.1916.
:
1, 400 μL). KF (5.3 mg, 0.090 mmol), KHCO3 (9.2 mg, 0.090 mmol), H2O2 (30% aq., 5.2 μL, 0.050 mmol) were added and the reaction mixture was heated to 40 °C for 3 h. The reaction was allowed to cool to rt, then it was diluted with CH2Cl2 and water. The organic extract was washed with water, dried (MgSO4), and concentrated. The product was purified by flash chromatography (2
:
1 pet. ether–ether) to afford 37 as a colourless oil (5.3 mg, 0.020 mmol, 43%); Rf 0.21 (2
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2349, 1734, 1667, 1434, 1262, 913, 745; 1H NMR (400 MHz, CDCl3) δH 3.75 (6H, s, CO2Me), 3.23–3.21 (4H, m, H1, H3), 2.42 (1H, dd, J = 17.0, 3.9 Hz, H5), 2.42–2.36 (1H, m, H7), 2.32–2.20 (1H, m, H6), 2.09 (1H, dd, J = 17.0, 12.0 Hz, H5), 2.07–2.00 (1H, m, H7), 1.07 (3H, d, J = 6.5 Hz, Me); 13C NMR (125 MHz, CDCl3) δC 194.9, 172.0 (2C), 158.7, 134.8, 57.8, 52.5 (2C), 45.8, 45.2, 38.6, 33.8, 31.0, 21.0; HRMS (ES+) calcd for C14H19O5 [M + H]+ 267.1227, found 267.1225.
:
1 pet. ether–ether) to afford 38 as a colourless oil (17.0 mg, 0.0374 mmol, 85%); Rf 0.31 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2923, 2853, 1740, 1460, 699; 1H NMR (500 MHz, CDCl3) δH 7.60–7.40 (6H, m, H5, H7, ArH), 7.33 (1H, t, J = 7.3 Hz, ArH), 4.08 (1H, septet, J = 6.1 Hz, CHMe2), 3.76 (6H, s, CO2Me), 3.74 (2H, s, H1 or H3), 3.63 (2H, s, H1 or H3), 1.19 (6H, d, J = 6.1 Hz, CHMe2), 1.03–0.93 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 172.2, 144.6, 141.5, 139.9, 139.4, 132.7, 132.5, 128.7, 127.1, 127.0, 124.3, 65.5, 60.4, 52.9, 41.4, 40.1, 25.8, 6.8, 5.5; HRMS (ES+) calcd for C26H34NaO5Si [M + Na]+ 477.2068, found 477.2053.
:
1 pet. ether–ether) to afford 39 as a colourless oil (27.0 mg, 0.0625 mmol, 93%); Rf 0.30 (5
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2958, 1733, 1596, 1433, 1259, 699; 1H NMR (500 MHz, CDCl3) δH 7.76 (2H, d, J = 8.3 Hz, ArH), 7.29 (2H, d, J = 8.3 Hz, ArH), 7.14 (1H, s, H5), 6.99 (1H, s, H7), 4.67 (2H, s, H3), 4.56 (2H, s, H1), 4.05 (1H, sept, J = 6.3 Hz, CHMe2), 2.40 (3H, s, Ts-Me), 2.31 (3H, s, Me), 1.18 (6H, d, J = 6.3 Hz, CHMe2), 0.92 (6H, t, J = 6.8 Hz, SiCH2Me), 0.88–0.82 (4H, m, SiCH2Me); 13C NMR (125 MHz, CDCl3) δC 143.4, 138.8, 136.3, 135.6, 134.4, 133.7, 131.1, 129.7, 127.6, 124.2, 65.4, 54.6, 53.3, 25.7, 21.4, 21.2, 6.8, 5.5; HRMS (ES+) calcd for C23H33NNaO3SSi [M + Na]+ 454.1843, found 454.1845.
:
1, 1 mL) was added and TBAF (1 M solution in THF, 13.0 μL, 0.013 mmol), KHCO3 (7.5 mg, 0.080 mmol) and H2O2 (30% aq., 13 μL, 0.12 mmol). The reaction mixture was heated to 60 °C for 3 h, then it was cooled to rt, diluted with CH2Cl2 and water. The organic phase was washed with water, dried (MgSO4), and concentrated. The residue was purified by flash chromatography (2
:
1 pet. ether–ether) to afford 40 (9.4 mg, 0.0288 mmol, 78%); Rf 0.15 (2
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2954, 1733, 1596, 1434, 1260, 1165, 864, 699; 1H NMR (500 MHz, CDCl3) δH 7.52 (2H, d, J = 7.5 Hz, ArH), 7.41 (2H, t, J = 7.5 Hz, ArH), 7.32 (1H, t, J = 7.5 Hz, ArH), 7.01 (1H, s, H7), 6.85 (1H, s, H5), 3.78 (6H, s, CO2Me), 3.66 (2H, s, H1), 3.60 (2H, s, H3); 13C NMR (125 MHz, CDCl3) δC 172.0, 151.8, 142.8, 142.5, 140.9, 128.7, 127.2, 127.1, 124.7, 115.6, 112.6, 60.3, 53.0, 40.9, 36.8; HRMS (ES−) calcd for C19H17O5 [M]− 325.1081, found 325.1081.
:
1, 1 mL) was added and TBAF (1 M solution in THF, 16.0 μL, 0.016 mmol), KHCO3 (9.0 mg, 0.10 mmol) and H2O2 (30% aq., 17 μL, 0.15 mmol). The reaction mixture was heated to 60 °C for 3 h, then it was cooled to rt, diluted with CH2Cl2 and water. The organic phase was washed with water, dried (MgSO4), and concentrated. The residue was purified by flash chromatography (2
:
1 pet. ether–ether) to afford 41 as a colourless oil (14.0 mg, 0.0461 mmol, 99%); Rf 0.26 (2
:
1 pet. ether–ether); IR (thin film) νmax/cm−1 2954, 1733, 1596, 1434, 1260, 1165, 864, 699; 1H NMR (500 MHz, CDCl3) δH 7.76 (2H, d, J = 7.7 Hz, ArH), 7.31 (2H, d, J = 7.7 Hz, ArH), 6.54 (1H, s, H7), 6.47 (1H, s, H5), 4.57 (4H, s, H1, H3), 2.40 (3H, s, TsMe), 2.24 (3H, s, Me); 13C NMR (125 MHz, CDCl3) δC 150.6, 143.6, 139.8, 138.2, 133.6, 129.8, 127.6, 119.7, 115.2, 114.8, 54.0, 51.4, 21.5, 21.2; HRMS (ES+) calcd for C16H17NNaO3S [M + Na]+ 326.0821, found 326.0824.
Footnote |
| † Electronic supplementary information (ESI) available: Copies of 1H and 13C NMR spectra, and experimental details for NMR experiments. See DOI: 10.1039/c4qo00123k |
| This journal is © the Partner Organisations 2014 |